Filtering by: Cancer Events

American Association for Clinical Chemistry (AACC)
Jul
24
to Jul 28

American Association for Clinical Chemistry (AACC)

  • McCormick Place Convention Center (map)
  • Google Calendar ICS

CLINICAL LAB EXPO HALL
Visit AACC 2022 DISRUPTIVE TECHNOLOGY AWARD SEMIFINALIST Biological Dynamics at the Clinical Lab Expo Hall to learn more about our unique technology for early cancer detection. The 2022 AACC Annual Scientific Meeting & Clinical Lab Expo showcases the latest science and technology shaping the future of laboratory medicine. The annual event features vital research and important changes in the field, with more than 250 educational opportunities in the form of lectures, plenary, scientific, and roundtable sessions. SEE DETAILS >>

From Plenaries featuring world-renowned scientists to cutting-edge Scientific Sessions and intimate Roundtables geared for lively discussion on hot topics, the 2022 AACC Annual Scientific Meeting & Clinical Lab Expo offers something for everyone in laboratory medicine.

AACC’s scientific program is designed to provide you with the knowledge you need to advance professionally, the skills to improve your practice, and opportunities to collaborate and learn from experts. Discover the meeting’s more than 250 educational opportunities in a variety of formats spanning the breadth of laboratory medicine. Use the Online Session Search to view the full conference program and find sessions by topic, speaker, or other features.

 

View Event →
International Society for Extracellular Vesicles (ISEV)
May
26
to May 30

International Society for Extracellular Vesicles (ISEV)

  • Lyon Convention Center (map)
  • Google Calendar ICS

POSTER PRESENTATION: Friday, May 27, 2022
3:15 PM – 4:15 PM CET
SESSION ROOM: Forum 5 & 6
TITLE: PF01 – Technologies and methods: EV separation from blood

David Searson, Senior Process Engineer, Biological Dynamics to present the company’s latest data for early cancer detection.

PRESENTATION ABSTRACT:
Electrokinetic Isolation of Extracellular Vesicles from Pancreatic, Ovarian and Bladder Cancers Enables Early Detection
Extracellular vesicles (EVs) carry cancer biomarkers and are central to emerging liquid biopsy technologies; however, current EV isolation methods balance purity against efficiency. We investigated an alternating current electrokinetic (ACE) method to isolate EVs directly from plasma. We compared the ACE method against differential ultracentrifugation (DU) to study yield, purity and utility. EVs isolated by ACE were then used for detection of early-stage pancreatic, ovarian, and bladder cancers.

The annual ISEV meeting offers an unparalleled opportunity to learn from, teach, and network with, leading and emerging experts in EV research. The scope and quality of the scientific exchange makes ISEV2022 the world’s largest and the premier meeting in EV research. This event features the best in vesicle science, covering all aspects of fundamental, translational, and clinical research, disseminating cutting-edge developments in EV research. ISEV2022 brings together scientists from academic, clinics, and industry, who have a common goal of understanding EVs and applying this knowledge for societal and economic benefit.

View Event →
American Urological Association (AUA) Annual Meeting
May
13
to May 16

American Urological Association (AUA) Annual Meeting

  • Ernest N. Morial Convention Center (map)
  • Google Calendar ICS

PRESENTATION: Monday, May 16, 2022
7:00 AM. – 9:00 AM CST
PODIUM PD53-07, Room 255/Abstract ID: 22-7466
TITLE: Bladder Cancer – Basic Research & Pathophysiology III

Jean M. Lewis, Ph.D., Associate Director, Research, Biological Dynamics to present the company’s latest bladder cancer data.

PRESENTATION ABSTRACT
Detection of Early-stage Bladder Cancer Using Plasma Extracellular Vesicle Protein Biomarkers
There is a need for earlier bladder cancer screening to reduce lifetime costs and improve patient outcomes. Urinary protein biomarkers have shown some promise, but reported sensitivities appear compromised by low and/or variable biomarker concentrations. In this study, we investigated the potential of using extracellular vesicles (EV) circulating in the blood to detect stage I and II bladder cancer. Using an alternating current electrokinetic (ACE) platform to purify EVs from plasma, we show how a multi-marker EV protein-based methodology can be used to discriminate bladder cancer cases from controls in stage I and II cases.

AUA continues to be a leader in developing innovative, evidence-based quality education for urologists and urologic health care professionals worldwide. Through the Annual Meeting—and other year-round educational offerings—the AUA sets the highest standards for urologic education.

The Annual Meeting, in its 117th year, is the largest gathering of urologists in the world, providing unparalleled access to groundbreaking research, new guidelines, and the latest advances in urologic medicine. Attendees repeatedly report that the knowledge they take from the meeting positively impacts their practices.

View Event →
American Association for Cancer Research (AACR) Annual Meeting
Apr
8
to Apr 13

American Association for Cancer Research (AACR) Annual Meeting

  • Ernest N. Morial Convention Center (map)
  • Google Calendar ICS

LIVE PRESENTATION
Sunday, April 10, 2022, 4:20 – 4:35 PM (ET)
SESSION CATEGORY: New Targets and Strategies for Prevention and Risk Reduction
SESSION TITLE: 727 – Detection of early-stage lung cancer using a liquid biopsy test based on extracellular vesicle proteins
PRESENTER: Juan P. Hinestrosa, PhD

VIRTUAL POSTER PRESENTATIONS:
Friday, April 8, 2022, 12:00 PM – 1:00 PM (ET)
SESSION CATEGORY: Preclinical Prevention, Early Detection, and Interception
SESSION TITLE: 5960 – Blood-based extracellular vesicle biomarker test for detection of early-stage pancreatic cancer
PRESENTER: Juan P. Hinestrosa, PhD

Friday, April 8, 2022, 12:00 PM – 1:00 PM (ET)
SESSION CATEGORY: Chemistry
SESSION TITLE: Proteomics and Mass Spectrometry
PERMANENT ABSTRACT NUMBER: 5082 – Proteomic analysis of extracellular vesicles from oncology donor samples purified using an alternating current electrokinetic microelectrode chip
PRESENTER: Jean M. Lewis, PhD

NOTE: Virtual posters are available online only and will not be presented live. Attendees can send questions to the presenter through the e-poster site or through the Networking feature of the virtual meeting platform. E-posters will be released at 12:00 PM CT on Friday, April 8, and will be available to registered attendees through Wednesday, July 13, 2022.

View Event →
Chief Medical Officer (CMO) Summit 360˚
Apr
4
to Apr 5

Chief Medical Officer (CMO) Summit 360˚

  • Boston Cambridge Marriott (map)
  • Google Calendar ICS

EVENT: Monday, April 4, 8:00 AM – Tuesday, April 5, 2022, 3:30 PM (ET)

PRESENTATION: Tuesday, April 5, 2022, 9:55 A.M. (ET)

Fireside Chat with Biological Dynamics
Dr. Paul Billings will discuss the interplay between therapeutic and diagnostic development; how molecular diagnostics impact therapeutic development; and using diagnostics to support revisiting data, global development, and global regulatory strategy.

Session Title: What Therapeutic Developers Should Look for in a Diagnostic Partner

View Event →
SelectBio: Circulating Biomarkers Europe
Mar
1
to Mar 2

SelectBio: Circulating Biomarkers Europe

EVENT: Tuesday, March 1, 2022, 08:00 Central European Time (CET) – Wednesday, March 2, 2022, 18:00 (CET)

PRESENTATION: Wednesday, March 2
11:00 AM CET/5:00 AM EST

Dr. Jean M. Lewis, Associate Director of Research at Biological Dynamics, Inc., will discuss her team’s work developing exosome-based liquid biopsy assays using the company’s proprietary platform. The presentation, Multi-Cancer Early Detection Based on a Classifier for Extracellular Vesicle Biomarkers, illustrates the potential utility of EV-protein biomarkers in the non-invasive diagnosis of cancer applications. Recently, her research has been directed towards identifying EV biomarkers for early-stage cancer liquid biopsy.

Presentation Abstract
Simultaneous detection of multiple, early-stage cancers was tested using extracellular vesicle (EV) bound protein markers from plasma purified by an alternating current electrokinetic (ACE) microarray. In a case-control study, this method detected 95.7% of pancreatic, 75.0% of ovarian, and 43.8% of bladder cancers at 99.5% specificity, all at stages I and II. The initial results suggest that this liquid biopsy screen may have great promise for early-stage, multi-cancer screening.

Session Title: Technology Developments in the Circulating Biomarkers Space

SelectBio Circulating Biomarkers Europe brings together academics and industry participants from around the world focused on research, biomarker analyses and therapeutics development leveraging the cargo from Exosomes and Extracellular Vesicles (EVs). An important component of this conference is to focus upon the development of Liquid Biopsies using circulating cell-free DNA (cfDNA), circulating tumor cells (CTCs) and other biomarkers found in biofluids.

Additionally, the conference focuses on the Therapeutic and Drug Delivery Opportunities Enabled by Extracellular Vesicles (EVs). In this vein, key opinion leaders in this space will be presenting at this conference.

Presentations, Panel Discussions and Round-Table Workshops from key opinion leaders in the field form the basis of this conference.

View Event →
Ovarian Cancer Alliance of San Diego Teal Steps Walk 2021
Sep
19
8:00 AM08:00

Ovarian Cancer Alliance of San Diego Teal Steps Walk 2021

Biological Dynamics is proud to sponsor the 6th annual Teal Steps Walk. The event supports community education and awareness outreach programs for ovarian cancer, the most lethal gynecologic cancer. Currently, there is no screening test for the early detection of ovarian cancer, and the overall five-year survival rate is only 45%. However, when detected early, the survival rate is over 90%.

Our participation in the event is closely aligned with our mission to improve global health and save lives by detecting cancer in blood at the earliest stages. We continue to see promising results from our experiments focused on stage I/II ovarian, pancreatic, and bladder cancers, which will advance the development of our multi-cancer screening test for early detection.

View Event →
Jun
16
12:10 PM12:10

Nephron Research Liquid Biopsy Innovation Symposium

12:10 – 12:40 PM ET / 9:10 – 9:40 AM PT

Nephron Research Liquid Biopsy Innovation Symposium (June 16, 2021)

CEO Raj Krishnan, Ph.D. and CFO Kevin Han, will be joined by Dr. Dave Hoon, Professor and Director, Translational Molecular Medicine and Genome Sequencing at Saint John's Cancer Institute to collaborate in a panel discussion, Novel Approaches for Early Cancer Detection, on Wednesday, June 16, 2021, at 12:10 p.m. ET / 9:10 a.m. PT.

Biological Dynamics will discuss a transformative approach to cancer screening using a proprietary platform that enables the isolation and evaluation of non-DNA biomarkers, such as exosomes, exo-proteins, and surfaceomes. The company will also discuss how the access to these differentiated biomarkers from blood can empower cancer detection at the earliest stages.

View Event →
Feb
17
to Feb 19

BTIG Virtual MedTech Digital Health Life Science and Diagnostic Tools Conference

Thursday, February 18, 2021
11:30 AM, ET / 8:30 AM, PT

Biological Dynamics’ CFO Kevin Han, and Mark Massaro, Sr. Equity Analyst at BTIG, participate in a virtual fireside chat. Follow the link below to join the presentation

Thursday, February 18, 2021
3:00 PM, ET / 12:00 PM, PT

Our CEO, Dr. Raj Krishnan, Mark Massaro, Sr. Equity Analyst at BTIG, and others will collaborate during an informative panel: Use of Cell-Free DNA, Protein Biomarkers and Other Omics For Early Cancer Detection.

View Event →